Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses.

Authors

B. Halmos

New York-Presbyterian Hospital, New York, NY

B. Halmos , P. Fu , N. A. Pennell , G. A. Otterson , T. Mekhail , M. R. Snell , J. P. Kuebler , S. M. Gadgeel , A. Conrad , A. T. Stefanski , A. Dowlati

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses.

First Author: Balazs Halmos

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.

First Author: Chul Kim

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

IFCT-1003 LADIE trial: Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC.

First Author: Julien Mazières

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase ΙΙ study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation.

First Author: Shintaro Kanda